TN2012000458A1 - Uses of dgat1 inhibitors - Google Patents

Uses of dgat1 inhibitors

Info

Publication number
TN2012000458A1
TN2012000458A1 TNP2012000458A TN2012000458A TN2012000458A1 TN 2012000458 A1 TN2012000458 A1 TN 2012000458A1 TN P2012000458 A TNP2012000458 A TN P2012000458A TN 2012000458 A TN2012000458 A TN 2012000458A TN 2012000458 A1 TN2012000458 A1 TN 2012000458A1
Authority
TN
Tunisia
Prior art keywords
chylomicronemia syndrome
hyperlipoproteinemia
progression
disease
prevention
Prior art date
Application number
TNP2012000458A
Other languages
English (en)
Inventor
Charles Meyers
Michael H Serrano-Wu
Tom Thuren
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44170024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000458(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2012000458A1 publication Critical patent/TN2012000458A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TNP2012000458A 2010-03-30 2012-09-24 Uses of dgat1 inhibitors TN2012000458A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31881410P 2010-03-30 2010-03-30
PCT/US2011/030234 WO2011123401A1 (en) 2010-03-30 2011-03-29 Uses of dgat1 inhibitors

Publications (1)

Publication Number Publication Date
TN2012000458A1 true TN2012000458A1 (en) 2014-01-30

Family

ID=44170024

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000458A TN2012000458A1 (en) 2010-03-30 2012-09-24 Uses of dgat1 inhibitors

Country Status (20)

Country Link
US (1) US9061012B2 (enExample)
EP (1) EP2552441B1 (enExample)
JP (2) JP2013523746A (enExample)
KR (1) KR20130073884A (enExample)
CN (1) CN102834099B (enExample)
AU (1) AU2011235301B2 (enExample)
BR (1) BR112012024618A2 (enExample)
CA (1) CA2792269A1 (enExample)
CL (1) CL2012002716A1 (enExample)
ES (1) ES2586127T3 (enExample)
MA (1) MA34097B1 (enExample)
MX (1) MX2012011333A (enExample)
NZ (1) NZ602125A (enExample)
PH (1) PH12012501859A1 (enExample)
RU (1) RU2012145950A (enExample)
SG (1) SG183529A1 (enExample)
TN (1) TN2012000458A1 (enExample)
TW (1) TW201136916A (enExample)
WO (1) WO2011123401A1 (enExample)
ZA (1) ZA201206456B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
CA2870886A1 (en) * 2012-04-25 2013-10-31 Korea Research Institute Of Chemical Technology Novel beta-alanine derivative, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
CA3170716A1 (en) * 2013-02-14 2014-08-21 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
BR112015027319A8 (pt) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc Métodos e composições para modular a expressão de apolipoproteína (a)
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CA2941401C (en) 2014-03-20 2019-06-11 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HK1231380A1 (zh) * 2014-06-26 2017-12-22 Cymabay Therapeutics, Inc. 严重高甘油三酯血症的治疗
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN111936137B (zh) 2018-03-16 2023-09-08 安济药业公司 用于治疗严重便秘的组合物和方法
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
MX2021000100A (es) 2018-07-13 2021-03-25 Gilead Sciences Inc Inhibidores de muerte programada-1 (pd-1)/ ligando de muerte programada 1 (pd-l1).
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
WO2020113041A1 (en) * 2018-11-30 2020-06-04 Hdl Therapeutics, Inc Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis
JP2021001143A (ja) * 2019-06-21 2021-01-07 小林製薬株式会社 乳び血漿改善剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045439A1 (en) 1996-05-30 1997-12-04 The Trustees Of Columbia University In The City Of New York Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
DE69939426D1 (de) 1998-06-24 2008-10-09 David Gladstone Inst Diacylglycerin o-acyltransferase
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
NZ539952A (en) 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
DE10331202A1 (de) * 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
US7300932B2 (en) 2003-08-07 2007-11-27 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
US20070249620A1 (en) 2004-07-02 2007-10-25 Hitoshi Kurata Urea Derivative
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1805156B1 (en) 2004-10-15 2010-12-22 Bayer HealthCare LLC Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
JP2006166742A (ja) * 2004-12-14 2006-06-29 Japan Health Science Foundation 高トリグリセリド血症の成因となる２種類のリポタンパクリパーゼ（ｌｐｌ）遺伝子変異及びそれを利用した高トリグリセリド血症を診断するためのｌｐｌ変異検出キット
MX2007007101A (es) 2004-12-14 2007-08-21 Astrazeneca Ab Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
MY155275A (en) * 2006-03-31 2015-09-30 Novartis Ag 4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-n-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
CA2719721C (en) * 2008-03-26 2012-12-18 Daiichi Sankyo Company, Limited Tetrahydroisoquinoline derivative

Also Published As

Publication number Publication date
CL2012002716A1 (es) 2013-01-25
SG183529A1 (en) 2012-10-30
EP2552441B1 (en) 2016-05-04
AU2011235301B2 (en) 2013-07-18
JP6251321B2 (ja) 2017-12-20
CA2792269A1 (en) 2011-10-06
JP2013523746A (ja) 2013-06-17
RU2012145950A (ru) 2014-05-10
US20130023495A1 (en) 2013-01-24
BR112012024618A2 (pt) 2019-09-24
EP2552441A1 (en) 2013-02-06
CN102834099B (zh) 2015-05-27
ES2586127T3 (es) 2016-10-11
US9061012B2 (en) 2015-06-23
KR20130073884A (ko) 2013-07-03
NZ602125A (en) 2014-01-31
ZA201206456B (en) 2013-05-29
PH12012501859A1 (en) 2013-01-07
JP2016216466A (ja) 2016-12-22
WO2011123401A1 (en) 2011-10-06
CN102834099A (zh) 2012-12-19
AU2011235301A1 (en) 2012-10-11
TW201136916A (en) 2011-11-01
MA34097B1 (fr) 2013-03-05
MX2012011333A (es) 2012-11-16

Similar Documents

Publication Publication Date Title
TN2012000458A1 (en) Uses of dgat1 inhibitors
IN2014DN10670A (enExample)
HK1211475A1 (en) Combination therapy
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
ZA201606320B (en) Human plasma kallikrein inhibitors
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
MY170935A (en) Neprilysin inhibitors
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EA201201201A1 (ru) Новые ингибиторы rock
SG191175A1 (en) Neprilysin inhibitors
NZ723772A (en) Neprilysin inhibitors
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
GEP20125708B (en) Hydroxamate-based inhibitors of deacetylases b
HK1205506A1 (en) Protein kinase inhibitors
MX343689B (es) Formulaciones combinadas de darunavir.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX341976B (es) Formulaciones de darunavir.
PH12016501548B1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
PH12013501830A1 (en) Peptide deformylase inhibitors
TN2012000568A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
WO2012128501A3 (ko) 포스포리파제Ｃ의 활성인자인 ｍ－３Ｍ３ＦＢＳ를 유효성분으로 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 약학적 조성물
WO2012044046A3 (en) Novel methylcyclohexane derivatives and uses thereof